Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Open-label Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies
jRCT2031220106Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ceralasertib in Non-hematologic malignancy, sponsored by AstraZeneca. Primary endpoints: Dose-limiting toxicity incidence and Safety and tolerability (adverse events). Started Jan 2021; status: completed.
02
Drugs
ceralasertib
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on jRCT2031220106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220106.